Vascular microRNAs: from disease mechanisms to therapeutic targets.
Vascular microRNAs: from disease mechanisms to therapeutic targets.
复制标题
DOI：
10.1161/circresaha.113.302762
复制
发表时间：
2014-01
影响因子：
20.1
通讯作者：
K. Stellos;S. Dimmeler
中科院分区：
文献类型：
--
作者：
K. Stellos;S. Dimmeler
动脉粥样硬化疾病，即冠状动脉疾病、外周动脉疾病和缺血性脑卒中的临床表现，仍然是当今发病率和死亡率的主要原因，尽管目前有大量心血管药物，并且医生和科学家共同付出了巨大努力来早期诊断和治疗这种已呈流行规模的疾病。除了将降脂作为动脉粥样硬化疾病的一个病因进行靶向治疗外，当前治疗动脉粥样硬化疾病的指南主要侧重于抗缺血和抗血栓治疗，这两种情况在疾病已经发展到动脉堵塞的程度时才会出现。动脉粥样硬化是一种与衰老密切相关的慢性非消退性炎症疾病。血管炎症是由大量血管细胞和免疫细胞分泌的一系列细胞因子和趋化因子所调控的。靶向一个甚至几个通路显然不足以逆转和有效治疗动脉粥样硬化疾病。因此，测试同时针对多种基因和细胞类型的治疗策略可能是有前景的。
The clinical manifestations of atherosclerotic disease, that is, coronary artery disease, peripheral arterial disease, and ischemic stroke, remain the major causes of morbidity and mortality today, despite the currently available plethora of cardiovascular medications and the enormous joint efforts of physicians and scientists to diagnose early and treat this disease that has attained pandemic proportions. Besides targeting lipid-lowering as a cause of atherosclerotic disease, the current guidelines to treat atherosclerotic disease focus mainly on anti-ischemic and antithrombotic therapy, 2 conditions that appear when the disease has already progressed to the point of occluding an artery. Atherosclerosis is a chronic nonresolving inflammatory disease that is strongly associated with aging. Vascular inflammation is orchestrated by a cascade of cytokines and chemokines secreted by a plethora of vascular cells and immune cells. Targeting one or even several pathways apparently is not enough to reverse and efficiently treat atherosclerotic disease. Thus, it might be promising to test therapeutic strategies that simultaneously target various genes and cell types.